Ke Wang1,2, Leila R Zelnick3,2, Yan Chen2,4, Andrew N Hoofnagle2,5, Terry Watnick6, Stephen Seliger6, Bryan Kestenbaum3,2. 1. Division of Nephrology, Department of Medicine and kewang@uw.edu. 2. Division of Nephrology, Kidney Research Institute, Kidney Research Institute, Seattle, Washington; and. 3. Division of Nephrology, Department of Medicine and. 4. Departments of Epidemiology and. 5. Laboratory Medicine, University of Washington, Seattle, Washington. 6. Division of Nephrology, Department of Medicine, University of Maryland, Baltimore, Maryland.
Abstract
BACKGROUND AND OBJECTIVES: In autosomal dominant polycystic kidney disease (ADPKD), the GFR often remains normal despite significant nephron loss. Proximal tubular secretory clearance may be reduced in ADPKD before detectable changes in GFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used targeted mass spectrometry to quantify secretory solutes from blood and urine samples from 31 patients with ADPKD and preserved GFR (mean eGFR =111±11 ml/min per 1.73 m2) and 25 healthy control individuals as well as from 95 patients with ADPKD and reduced GFR (mean eGFR =53±21 ml/min per 1.73 m2) and 92 individuals with non-ADPKD CKD. We used linear regression to compare the fractional excretion of each solute between ADPKD and control groups. Among 112 patients with ADPKD, we used linear regression to determine associations of solute fractional excretion with height-adjusted total kidney volume. RESULTS: After adjusting for demographics, clinical characteristics, and kidney function measures, the fractional excretions of three secretory solutes were lower in patients with ADPKD and preserved GFR compared with healthy individuals: 52% lower cinnamoylglycine excretion (95% confidence interval, 24% to 70%), 53% lower tiglylglycine excretion (95% confidence interval, 23% to 71%), and 91% lower xanthosine excretion (95% confidence interval, 83% to 95%). In addition to lower excretions of tiglylglycine and xanthosine, patients with ADPKD and reduced GFR also demonstrated 37% lower dimethyluric acid excretion (95% confidence interval, 21% to 50%), 58% lower hippurate excretion (95% confidence interval, 48% to 66%), 48% lower isovalerylglycine excretion (95% confidence interval, 37% to 56%), and 31% lower pyridoxic acid excretion (95% confidence interval, 16% to 42%) compared with patients with non-ADPKD CKD and comparable eGFR. Among patients with ADPKD, solute fractional excretions were not associated with differences in kidney volume. CONCLUSIONS: Patients with ADPKD and preserved and reduced GFR demonstrate lower tubular secretory solute excretion compared with healthy controls and patients with non-ADPKD CKD. Our results suggest that tubular secretion is impaired in ADPKD independent of GFR.
BACKGROUND AND OBJECTIVES: In autosomal dominant polycystic kidney disease (ADPKD), the GFR often remains normal despite significant nephron loss. Proximal tubular secretory clearance may be reduced in ADPKD before detectable changes in GFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used targeted mass spectrometry to quantify secretory solutes from blood and urine samples from 31 patients with ADPKD and preserved GFR (mean eGFR =111±11 ml/min per 1.73 m2) and 25 healthy control individuals as well as from 95 patients with ADPKD and reduced GFR (mean eGFR =53±21 ml/min per 1.73 m2) and 92 individuals with non-ADPKD CKD. We used linear regression to compare the fractional excretion of each solute between ADPKD and control groups. Among 112 patients with ADPKD, we used linear regression to determine associations of solute fractional excretion with height-adjusted total kidney volume. RESULTS: After adjusting for demographics, clinical characteristics, and kidney function measures, the fractional excretions of three secretory solutes were lower in patients with ADPKD and preserved GFR compared with healthy individuals: 52% lower cinnamoylglycine excretion (95% confidence interval, 24% to 70%), 53% lower tiglylglycine excretion (95% confidence interval, 23% to 71%), and 91% lower xanthosine excretion (95% confidence interval, 83% to 95%). In addition to lower excretions of tiglylglycine and xanthosine, patients with ADPKD and reduced GFR also demonstrated 37% lower dimethyluric acid excretion (95% confidence interval, 21% to 50%), 58% lower hippurate excretion (95% confidence interval, 48% to 66%), 48% lower isovalerylglycine excretion (95% confidence interval, 37% to 56%), and 31% lower pyridoxic acid excretion (95% confidence interval, 16% to 42%) compared with patients with non-ADPKD CKD and comparable eGFR. Among patients with ADPKD, solute fractional excretions were not associated with differences in kidney volume. CONCLUSIONS: Patients with ADPKD and preserved and reduced GFR demonstrate lower tubular secretory solute excretion compared with healthy controls and patients with non-ADPKD CKD. Our results suggest that tubular secretion is impaired in ADPKD independent of GFR.
Authors: Joachim H Ix; Christina L Wassel; Lesley A Stevens; Gerald J Beck; Marc Froissart; Gerjan Navis; Roger Rodby; Vicente E Torres; Yaping Lucy Zhang; Tom Greene; Andrew S Levey Journal: Clin J Am Soc Nephrol Date: 2010-10-21 Impact factor: 8.237
Authors: William R Wikoff; Megha A Nagle; Valentina L Kouznetsova; Igor F Tsigelny; Sanjay K Nigam Journal: J Proteome Res Date: 2011-04-22 Impact factor: 4.466
Authors: Sandra L Taylor; Sheila Ganti; Nikolay O Bukanov; Arlene Chapman; Oliver Fiehn; Michael Osier; Kyoungmi Kim; Robert H Weiss Journal: Am J Physiol Renal Physiol Date: 2010-02-03
Authors: Astrid M Suchy-Dicey; Thomas Laha; Andrew Hoofnagle; Rick Newitt; Tammy L Sirich; Timothy W Meyer; Ken E Thummel; N David Yanez; Jonathan Himmelfarb; Noel S Weiss; Bryan R Kestenbaum Journal: J Am Soc Nephrol Date: 2015-11-27 Impact factor: 10.121
Authors: Eun Young Park; Bo Hye Kim; Eun Ji Lee; EunSun Chang; Dae Won Kim; Soo Young Choi; Jong Hoon Park Journal: J Biol Chem Date: 2014-02-10 Impact factor: 5.157
Authors: Yan Chen; Leila R Zelnick; Andrew N Hoofnagle; Catherine K Yeung; Laura M Shireman; Brian Phillips; Calder C Brauchla; Ian de Boer; Linda Manahan; Susan R Heckbert; Jonathan Himmelfarb; Bryan R Kestenbaum Journal: J Am Soc Nephrol Date: 2020-11-25 Impact factor: 10.121
Authors: Pranav S Garimella; Ronit Katz; Sushrut S Waikar; Anand Srivastava; Insa Schmidt; Andrew Hoofnagle; Ragnar Palsson; Helmut G Rennke; Isaac E Stillman; Ke Wang; Bryan R Kestenbaum; Joachim H Ix Journal: Am J Kidney Dis Date: 2021-09-24 Impact factor: 11.072
Authors: Yan Chen; Leila R Zelnick; Matthew P Huber; Ke Wang; Nisha Bansal; Andrew N Hoofnagle; Rajan K Paranji; Susan R Heckbert; Noel S Weiss; Alan S Go; Chi-Yuan Hsu; Harold I Feldman; Sushrut S Waikar; Rupal C Mehta; Anand Srivastava; Stephen L Seliger; James P Lash; Anna C Porter; Dominic S Raj; Bryan R Kestenbaum Journal: Am J Kidney Dis Date: 2021-01-07 Impact factor: 11.072
Authors: Pavan K Bhatraju; Xin-Ya Chai; Neha A Sathe; John Ruzinski; Edward D Siew; Jonathan Himmelfarb; Andrew N Hoofnagle; Mark M Wurfel; Bryan R Kestenbaum Journal: JCI Insight Date: 2021-05-24